Get the Stockscreener App
68.76
6.27%
-4.60
Pre-market:
68.00
-0.76
-1.11%
Cg Oncology Inc stock is traded at $68.76, with a volume of 1.44M.
It is down -6.27% in the last 24 hours and down -12.11% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$73.36
Open:
$73.1
24h Volume:
1.44M
Relative Volume:
1.53
Market Cap:
$6.09B
Revenue:
$5.07M
Net Income/Loss:
$-186.75M
P/E Ratio:
-29.35
EPS:
-2.3424
Net Cash Flow:
$-160.43M
1W Performance:
-9.07%
1M Performance:
-12.11%
6M Performance:
+7.71%
1Y Performance:
+87.46%
1-Day Range:
$68.15
$73.44
1-Week Range:
$68.15
$80.63
52-Week Range:
$35.64
$80.97
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 409-3700
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare CGON vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
68.76 | 6.09B | 5.07M | -186.75M | -160.43M | -2.3424 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
After $7.9M sale, CG Oncology (NASDAQ: CGON) officer plans more stock trades - Stock Titan
CG Oncology (NASDAQ: CGON) officer sold 100,000 shares and now plans more - Stock Titan
CG Oncology (NASDAQ: CGON) director sells shares under preset trading plan - Stock Titan
CGON: Durable efficacy, operational simplicity, and pivotal trial catalysts drive strong outlook - TradingView
CG Oncology at Morgan Stanley conference: launch, data and scale By Investing.com - Investing.com Canada
Planned CG Oncology (NASDAQ: CGON) insider sale totals 826 shares - Stock Titan
CG Oncology at Cantor conference: cretostimogene nears key readout By Investing.com - Investing.com Canada
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)? - Zacks Investment Research
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run - Yahoo Finance
CG Oncology (CGON) officer to sell 29,630 shares after prior 100K trades - Stock Titan
CG Oncology to Present at Upcoming Investor Conferences in September - manilatimes.net
Morgan Stanley and Cantor Fitzgerald conferences will include talks by CG Oncology’s CEO in New York. - Stock Titan
Bank of New York Mellon Corp Invests $16.58 Million in CG Oncology, Inc. $CGON - marketbeat.com
CG Oncology (NASDAQ: CGON) officer lines up new sale after $7.9M August trades - Stock Titan
CG Oncology (NASDAQ: CGON) holder plans 5,789-share sale from option exercise - Stock Titan
ADAR1 Capital Management LLC Invests $8.43 Million in CG Oncology, Inc. $CGON - MarketBeat
Another California giant bolts for Texas as multi-billion-dollar company announces move - New York Post
CG Oncology (NASDAQ: CGON) officer eyes new sale after $7.9M August stock trade - Stock Titan
CG Oncology Leaves Irvine for Dallas - Orange County Business Journal
RTW INVESTMENTS, LP Boosts CG Oncology Inc (CGON) Stake -- Shares Look 38% Undervalued on GF Value - GuruFocus
Jefferies Group's CG Oncology Inc(CGON) Holding History - GuruFocus
Investigation launched into CG Oncology officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm - PR Newswire
How Investors May Respond To CG Oncology (CGON) Revenue Growth Alongside a Widening Net Loss - simplywall.st
CG Oncology (NASDAQ: CGON) insider flags $7.95M stock sale after recent disposals - Stock Titan
CG Oncology stock hits all-time high of 79.5 USD By Investing.com - Investing.com Nigeria
CG Oncology stock hits all-time high of 79.5 USD - Investing.com
CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup - ChartMill
CG (CGON) Financial Update: EPS Misses Its Estimate in the Reported Period; Share Move: The Stock Ends Up 5.75% at the CloseQuarterly Earnings - careplusvn.com
CG Oncology director sells 1,000 shares at $74.54 | CGON Insider Trading - Stock Titan
Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal
CG Oncology (NASDAQ: CGON) insider lines up new stock sale - Stock Titan
CGON shareholder (NASDAQ: CGON) details planned 19,364-share stock sale - Stock Titan
CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds - Stock Titan
CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares - Stock Titan
CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects. - Pluang
CG Oncology: Circling Back After Huge Rally - Seeking Alpha
CGON (CGON) investor lists 25,989-share sale after series of stock disposals - Stock Titan
CG Oncology (CGON) Falls 2.96% as Shares Approach Key Support at $70.97Institutional Volume - Vinanet
CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position - Stock Titan
Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $85 - Moomoo
CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise - Stock Titan
CGON (CGON) insider Ambaw Bellete plans 50,000-share stock sale - Stock Titan
CG Oncology (NASDAQ:CGON) Hits New 52-Week HighShould You Buy? - marketbeat.com
CG Oncology, Inc. (CGON) Stock Analysis: A Potential 18.96% Upside In The Biotech Sector - DirectorsTalk Interviews
CG Oncology (CGON) Edges Higher as Shares Consolidate Above Key SupportUpthrust Pattern - dars.gov.et
CGON (CGON) insider plans 50,000-share stock sale after option exercise - Stock Titan
HC Wainwright Has Weak Estimate for CG Oncology Q3 Earnings - MarketBeat
CG Oncology Inc (CGON) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $85 to $108 - Moomoo
Enterprise value to EBITDA forward of CG Oncology, Inc. – NASDAQ:CGON - TradingView
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):